Data completeness
0/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HISERPIA (reserpine) is an oral tablet antihypertensive agent in pre-launch development by Teva. Reserpine is a rauwolfia alkaloid that works as a monoamine depleter, reducing sympathetic nervous system activity to lower blood pressure. It is indicated for hypertension management in patients requiring alternative or adjunctive antihypertensive therapy.
Pre-Launch
Pre-launch stage indicates emerging commercial opportunity with limited team infrastructure; career growth potential depends on successful FDA approval and market penetration strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HISERPIA at pre-launch offers hands-on opportunity to build a brand from ground zero, with exposure to regulatory approval processes, launch strategy, and payer negotiations. Career value is moderate to high for commercial professionals seeking launch experience, but long-term tenure may be limited by competitive pressures and lack of patent protection.
Brand Manager
Worked on HISERPIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.